|
|||||
|
|
A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study |
|
| Authors: | Maryam Fouladi MD John P. Perentesis MD Christine L. Phillips MD Sarah Leary MD Joel M. Reid PharmD Renee M. McGovern Ashish M. Ingle MSc Charlotte H. Ahern PhD Matthew M. Ames PharmD Peter Houghton PhD L. Austin Doyle MD Brenda Weigel MD Susan M. Blaney MD |
| Affiliation: | 1. Cincinnati Children's Hospital Medical Center, , Cincinnati, Ohio;2. Children's Hospital and Regional Medical Center, , Seattle, Washington;3. Mayo Clinic, College of Medicine, , Rochester, Minnesota;4. Children's Oncology Group, , Arcadia, California;5. Nationwide Children's Hospital, , Columbus, Ohio;6. National Cancer Institute, , Rockville, Maryland;7. University of Minnesota, , Minneapolis, Minnesota;8. Texas Children's Cancer Center, , Houston, Texas |
| Abstract: | |
| Keywords: | AKT inhibitor MK‐2206 pediatric phase I trial relapsed solid tumors |